Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -839K | -112K | -15K |
| Operating Income | -125M | -83M | -36M | -10M |
| EBITDA | -124M | -77M | -35M | -10M |
| Net Income | -111M | -78M | -35M | -11M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$37.34
+1.27% today
1Y Change
+243.20%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rapport Therapeutics, Inc. Common Stock (RAPP) is a Healthcare stock with a market cap of $1.24B and listed on NASDAQ. The stock last traded around $37.34 and up 243.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -652.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -652.6%, free cash flow -31.0% with operating margin 0.0% and ROIC -25.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RAPP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RAPP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RAPP Max Drawdown
-28.82%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RAPP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$10.7M
+69.4% YoY
Free Cash Flow
-$3.5M
+87.8% YoY
Revenue Growth
+0.0%
EPS Growth
-652.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -839K | -112K | -15K |
| Operating Income | -125M | -83M | -36M | -10M |
| EBITDA | -124M | -77M | -35M | -10M |
| Net Income | -111M | -78M | -35M | -11M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 53M | 57M | 70M | 31M |
| Total Assets | 512M | 315M | 155M | 32M |
| Total Liabilities | 28M | 10M | 181M | 12M |
| Shareholder Equity | 485M | 305M | -26M | 20M |
| Total Debt | 11M | 1M | 2M | 10M |
| Net Debt | -41M | -55M | -68M | -21M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+88.1% YoY
Capital Expenditures
284K
+82.6% YoY
Free Cash Flow
4M
+87.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-28.9%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.